Drug Trial Radar · NCT04856969
Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Mar 30, 2021
Primary completion
May 4, 2021
Study completion May 4, 2021
Sponsor
- Lead sponsor
- AutotelicbioIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the interaction between two investigational products by comparing and analyzing pharmacokinetic interactions and safety in steady state after multiple oral administration of ATB-1011 or ATB-1012 alone or in combination in healthy adult volunteers.
Conditions
- Healthy Adult Volunteers
Interventions
OlmesartanDrug
First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
DapagliflozinDrug
First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- ATB-1011 AUCτ,ssTime frame: 5days, 10days
- ATB-1012 AUCτ,ss,Time frame: 5days, 10days
- ATB-1011 Cmax,ssTime frame: 5days, 10days
- ATB-1012 Cmax,ssTime frame: 5days, 10days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H Plus Yangji Hospital
Seoul, Gwanak-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.